NO20053344L - Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. - Google Patents

Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Info

Publication number
NO20053344L
NO20053344L NO20053344A NO20053344A NO20053344L NO 20053344 L NO20053344 L NO 20053344L NO 20053344 A NO20053344 A NO 20053344A NO 20053344 A NO20053344 A NO 20053344A NO 20053344 L NO20053344 L NO 20053344L
Authority
NO
Norway
Prior art keywords
genetically modified
generating
organism
modified organism
active substances
Prior art date
Application number
NO20053344A
Other languages
English (en)
Other versions
NO20053344D0 (no
Inventor
Almut Nitsche
Ekkehard Leberer
Bert Klebl
Anja Stadler
Rosemarie Sollner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20053344D0 publication Critical patent/NO20053344D0/no
Publication of NO20053344L publication Critical patent/NO20053344L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
NO20053344A 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. NO20053344L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10258885A DE10258885A1 (de) 2002-12-17 2002-12-17 Verfahren zur Generierung eines gentechnisch veränderten Organismus
PCT/EP2003/012870 WO2004055206A1 (de) 2002-12-17 2003-11-18 Verfahren zur generierung eines gentechnisch veränderten organismus für das wirk substanzscreening

Publications (2)

Publication Number Publication Date
NO20053344D0 NO20053344D0 (no) 2005-07-08
NO20053344L true NO20053344L (no) 2005-07-08

Family

ID=32519000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053344A NO20053344L (no) 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Country Status (14)

Country Link
US (1) US20040143854A1 (no)
EP (1) EP1576186B1 (no)
JP (1) JP4630067B2 (no)
KR (2) KR20120038025A (no)
CN (1) CN1726290B (no)
AT (1) ATE508201T1 (no)
AU (1) AU2003283409A1 (no)
CA (1) CA2509333A1 (no)
DE (2) DE10258885A1 (no)
HK (1) HK1087734A1 (no)
NO (1) NO20053344L (no)
RU (1) RU2376364C2 (no)
WO (1) WO2004055206A1 (no)
ZA (1) ZA200504212B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2574953A1 (en) * 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
WO2007124115A2 (en) * 2006-04-20 2007-11-01 Trustees Of Boston College Compositions and methods for identifying inhibitors and activators of cyclic amp phosphodiesterases
US8008332B2 (en) * 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP6109740B2 (ja) * 2010-10-29 2017-04-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ３３のｎ末端ドメインが欠失している炎症マウスモデル
HUP1100657A2 (en) * 2011-11-29 2013-06-28 Eotvos Lorand Tudomanyegyetem Transgenic caenorhabditis elegans
CN110172454B (zh) * 2019-05-23 2020-11-13 浙江大学 一种s-腺苷甲硫氨酸合成酶突变体及其高通量筛选方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030012A1 (en) * 1994-04-26 1995-11-09 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
AU1582799A (en) * 1997-11-07 1999-05-31 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
AU2596800A (en) * 1998-12-31 2000-07-31 Iconix Pharmaceuticals, Inc. Method for generating a pathway reporter system
AU2108201A (en) * 1999-12-22 2001-07-03 Iconix Pharmaceuticals, Inc. Synthetic lethal expression screen
CA2437383A1 (en) * 2001-02-02 2002-08-15 Raymond Kim Alteration of phenotype due to heterologous genes
US20030044866A1 (en) * 2001-08-15 2003-03-06 Charles Boone Yeast arrays, methods of making such arrays, and methods of analyzing such arrays

Also Published As

Publication number Publication date
NO20053344D0 (no) 2005-07-08
CA2509333A1 (en) 2004-07-01
DE10258885A1 (de) 2004-07-15
JP2006509512A (ja) 2006-03-23
DE50313671D1 (de) 2011-06-16
RU2005122470A (ru) 2006-05-10
CN1726290A (zh) 2006-01-25
HK1087734A1 (en) 2006-10-20
JP4630067B2 (ja) 2011-02-09
KR20120038025A (ko) 2012-04-20
ZA200504212B (en) 2006-02-22
CN1726290B (zh) 2012-09-05
ATE508201T1 (de) 2011-05-15
AU2003283409A1 (en) 2004-07-09
EP1576186B1 (de) 2011-05-04
KR20050085806A (ko) 2005-08-29
EP1576186A1 (de) 2005-09-21
KR101215854B1 (ko) 2012-12-31
WO2004055206A1 (de) 2004-07-01
RU2376364C2 (ru) 2009-12-20
US20040143854A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
NO20053344L (no) Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.
ATE269414T1 (de) Verfahren zur drogenuntersuchung
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
ATE516497T1 (de) Screening für funktionshomologien
ATE397752T1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
DE60336419D1 (de) Selektive synthese von organophosphiten
DE60035196D1 (de) Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden
DE60232059D1 (de) Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
ATE471336T1 (de) Das biomolekültransduktionsmotiv mph-1-btm und dessen verwendung
ATE351902T1 (de) Oberflächentransfektion und expressionsverfahren
ATE217905T1 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
CY1108849T1 (el) Πολλαπλασιαμος του ιου κορωνα των βοοειδων σε κυτταρα ωοθηκων κινεζικων κρικητων
SE0002189D0 (sv) New method and assay
WO2003094841A3 (en) Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes
Nakamura The Role of Mechanotransduction in Contact Inhibition of Locomotion and Proliferation
ATE501278T1 (de) Verfahren zur verwendung von il-21
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
EP1581645A4 (en) METHOD OF USING INTERRUPTED DIVISION CELLS IN SCREENING TESTS
Kaiser et al. Expanding horizons at Big Sky: Symposium on Ubiquitin and Signaling
AU2003241174A8 (en) Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc
Cui et al. Metabolic regulation of mRNA splicing
DE60234097D1 (de) Chimere proteine zum targeting von zellen und der induktion von apoptose, und verfahren zu deren verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application